One-year dynamics of antibody titers after three doses of SARS-CoV-2 BNT162b2 vaccine.
COVID-19
Humoral response
Pfizer-BioNTech vaccine
SARS-CoV-2
Vaccination
Journal
Vaccine
ISSN: 1873-2518
Titre abrégé: Vaccine
Pays: Netherlands
ID NLM: 8406899
Informations de publication
Date de publication:
23 Jan 2023
23 Jan 2023
Historique:
received:
12
03
2022
revised:
14
12
2022
accepted:
17
12
2022
pubmed:
25
12
2022
medline:
25
1
2023
entrez:
24
12
2022
Statut:
ppublish
Résumé
A third dose of the BNT162b2 SARS-CoV-2 vaccine leads to a significant increase in antibody levels, however, concerns regarding the long-term persistence of this response exist. We assessed the humoral response for one year following vaccination. A prospective study among immunocompetent healthcare workers (HCW) who received three doses of BNT162b2. anti-spike antibody titers were measured at six predefined timepoints, from before the second vaccine dose, and up to one year afterwards, which is 4-6 months after the third dose. HCW with a history of SARS-CoV-2 infection were excluded. Seventy-six HCW had all the six serological measurements. Antibody titers significantly increased shortly following the third vaccine dose, and while declining, remained higher from all previous measurements for up to six months. A third dose of BNT162b2 leads to a profound humoral response, which remains significantly higher than previous measurements, even after 6 months.
Sections du résumé
BACKGROUND
BACKGROUND
A third dose of the BNT162b2 SARS-CoV-2 vaccine leads to a significant increase in antibody levels, however, concerns regarding the long-term persistence of this response exist. We assessed the humoral response for one year following vaccination.
METHODS
METHODS
A prospective study among immunocompetent healthcare workers (HCW) who received three doses of BNT162b2. anti-spike antibody titers were measured at six predefined timepoints, from before the second vaccine dose, and up to one year afterwards, which is 4-6 months after the third dose. HCW with a history of SARS-CoV-2 infection were excluded.
RESULTS
RESULTS
Seventy-six HCW had all the six serological measurements. Antibody titers significantly increased shortly following the third vaccine dose, and while declining, remained higher from all previous measurements for up to six months.
CONCLUSIONS
CONCLUSIONS
A third dose of BNT162b2 leads to a profound humoral response, which remains significantly higher than previous measurements, even after 6 months.
Identifiants
pubmed: 36566162
pii: S0264-410X(22)01567-5
doi: 10.1016/j.vaccine.2022.12.042
pmc: PMC9767891
pii:
doi:
Substances chimiques
COVID-19 Vaccines
0
BNT162 Vaccine
0
Antibodies, Viral
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
871-874Informations de copyright
Copyright © 2022 Elsevier Ltd. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Références
JAMA. 2021 Dec 7;326(21):2203-2204
pubmed: 34739043
Lancet Infect Dis. 2020 Dec;20(12):1390-1400
pubmed: 32979318
N Engl J Med. 2021 Nov 4;385(19):1761-1773
pubmed: 34525277
N Engl J Med. 2022 May 12;386(19):1804-1816
pubmed: 35263534
Nat Med. 2021 Jul;27(7):1205-1211
pubmed: 34002089
Lancet Microbe. 2022 Jan;3(1):e52-e61
pubmed: 34806056
N Engl J Med. 2021 Oct 14;385(16):1474-1484
pubmed: 34320281
Vaccine. 2021 Jul 22;39(32):4423-4428
pubmed: 34210573
Vaccine. 2022 Jan 28;40(4):650-655
pubmed: 34952755
J Nephrol. 2022 Jun;35(5):1479-1487
pubmed: 35175577
Ann Intern Med. 2022 Mar;175(3):371-378
pubmed: 34904856
Lancet Healthy Longev. 2022 Jan;3(1):e13-e21
pubmed: 34935001
Microorganisms. 2021 Aug 13;9(8):
pubmed: 34442806
N Engl J Med. 2021 Oct 7;385(15):1393-1400
pubmed: 34525275
Cell. 2022 Feb 3;185(3):457-466.e4
pubmed: 34995482